摘要
目的探讨1剂赛尼哌在预防同种异体肾移植急性排斥反应中的作用。方法回顾性分析50例应用1剂赛尼哌的肾移植患者资料,同期30例未应用赛尼哌患者作为对照,随访6个月。分析比较2组患者急性排斥反应、移植肾功能、感染及赛尼哌不良反应发生情况。结果赛尼哌组发生急性排斥反应13例(26%),对照组为17例(57%),差异有统计学意义(P<0.05),2组患者药物不良作用方面、血液系统损害、肝功能损害、感染发生率及人/肾存活率差异无统计学意义(P>0.05)。结论联合应用1剂赛尼哌免疫抑制方案可以降低肾移植急性排斥反应发生率,改善移植肾功能,不良反应轻。
Objective To investigate the role of zenapax in the prevention of acute rejection in renal transplant recipients. Methods The medical records of 50 renal transplant recipients treated with one close of zenapax （ study group） and simultaneously 30 renal transplant recipients without treatment of zenapax （control group） were retrospectively analyzed. The follow-up was six months. The incidence of acute rejection,renal allograft function, infection, and adverse effects of zenapax were comparatively analyzed between the 2 groups. Results Acute rejection rate was lower in study group （ 13/50,26% ） compared with that in control group （ 17/30,57% ; P 〈 0.05 ）. The differences of adverse events, damage to liver function and blood system, infection rate, and person-allografi survival between the 2 groups were not significant （ P 〉 0.05）. Conclusions One close regimen of zenapax as part of immunosuppressive therapy is effective in the prevention of acute rejection in renal transplant recipients. It has less side effects and contributes to the improvement of renal allograft function.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2005年第10期675-678,共4页
Chinese Journal of Urology
